Latest News

Stocks in Play

Dividend Stocks

Breakout Stocks

Tech Insider

CAD Daily Briefing

US Markets

Stocks To Watch

The Week Ahead



Commodity News

Metals & Mining News

Crude Oil News

Crypto News

M & A News


OTC Company News

TSX Company News

Earnings Announcements

Dividend Announcements

These Companies Want to Give You LSD to Treat a Range of Mental Health Issues

Psychedelics could rapidly change the way we address mental and other health issues.

After years of being written off, psychedelics – like LSD, MDMA, and psilocybin are finding their way back into the spotlight. All thanks in part to clinical trials from major institutions that have found such drugs can effectively treat obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, eating disorders, depression, and anxiety.

With LSD for example, doctors first used it to treat issues such as anxiety, depression, and anxiety during the 1950s and 1960s, says While the drug has since been written off, it may soon make a comeback, with companies like MindMed proposing to use a high-dose LSD treatment to help treat anxiety. To make that happen, the company must first apply to use LSD as an Investigational New Drug (IND) with the US FDA. If successful, it could lead to incredible opportunities for companies such as The Yield Growth Corp. (CSE:BOSS)(OTC:BOSQF), Champignon Brands Inc. (OTC:SHRMF)(CSE:SHRM), Mind Medicine Inc. (OTC:MMEDF), Revive Therapeutics Ltd. (CSE:RVV)(OTC:RVVTF), and Numinus Wellness Inc. (TSXV:NUMI).

The Yield Growth Corp. (CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWSThe Yield Growth Corp. announced that its majority owned subsidiary NeonMind has filed an additional provisional patent application related to using psychedelics as medicine. The patent application covers the administration of a compound selected from the group consisting of lysergic acid diethylamide and d-lysergic acid amide (and compounds with similar molecular structure) in combination with a 5-HT2A antagonist to treat compulsive eating disorder, obesity and related illnesses.

The patent application was filed by NeonMind on June 5, 2020, and Translational Life Sciences Inc. has a 20% interest as a co-collaborator on the development of intellectual property. “Our research with our scientific team into using psilocybin to treat compulsive eating and food cravings has led to paths of inquiry for research into expanded medical uses of psychedelics,” says Penny White, NeonMind CEO, “we are excited to lay the groundwork for new areas of potential research for the future.”

The global projected market for weight loss and weight management treatment is estimated at USD $245 billion, according to MarketsandMarkets. The global projected market for diabetes treatment is estimated at $87 billion US Dollars, according to Modor Intelligence.

Research and development involving controlled substances such as psilocybin, LSD and LSA in Canada can only be conducted with approval by Health Canada. Section 56 of the Controlled Drug and Substances Act (Canada) grants Health Canada the right to give exemptions for research into controlled substances.

Other related developments from around the markets include:

Champignon Brands Inc. (OTC:SHRMF)(CSE:SHRM) a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, announced it has selected Toronto-based Dalriada Drug Discovery Inc. to advance its new chemical entity IP portfolio as it pertains to ketamine and psilocybin/psilicin molecular scaffolds. Dalriada, a leading contract research organization (CRO) in the drug discovery space, will lead Champignon’s new drug discovery programs in the NCE arena and further provide integrated R&D support to accelerate the Company’s existing preclinical assets and ongoing development of proprietary delivery platforms. The Company anticipates that through this partnership, a robust pipeline of preclinical and clinical assets with strong IP protection will be delivered.  “It is with great pleasure to the welcome the Dalriada group to Champignon,” commented Dr. Joseph Gabriele, Special Advisor, Champignon. “Dalriada’s expertise in medicinal chemistry will be a monumental addition to Champignon’s innovative diverse formulation platforms by their expertise in the synthesis of molecules, including existing psychedelics (ketamine, psilocybin and MDMA), as well as novel new psychedelic-like molecules. This synergistic collaboration will differentiate Champignon from other companies in the psychedelic space by boosting our ability to maintain an inhouse infrastructure for the clinical delivery NCEs.”

Mind Medicine Inc. (OTC:MMEDF) s supporting and collaborating on a Phase 2 clinical trial evaluating LSD for the treatment of cluster headaches at University Hospital Basel’s Liechti Lab. The Phase 2 trial began recruiting patients in early January and has commenced treating patients with LSD. MindMed is the leading neuro-pharmaceutical company for psychedelic inspired medicines and previously formed an ongoing R&D collaboration with the University Hospital Basel’s Liechti Lab, the leading global clinical research laboratory for LSD, to evaluate multiple therapeutic uses of psychedelics and next-gen psychedelic therapies. This new development is part of the collaboration and Dr Matthias Liechti is serving as principal investigator of the clinical trial. Cluster headaches, also known as “suicide headaches,” due to the severity of the pain caused are often viewed as one of the most profoundly painful conditions known to mankind. The pain occurs on one side of the head or above an eye and can last for weeks or months. Studies have demonstrated increased suicidality associated with patients experiencing cluster headache attacks.

Revive Therapeutics Ltd. (CSE:RVV)(OTC:RVVTF) a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced that it has filed its Clinical Trial Application with Health Canada and provides an update on the filing of its Investigational New Drug package to the U.S. Food and Drug Administration for the proposed Phase 3 confirmatory clinical trial (“Phase 3 study”) to evaluate Bucillamine in the treatment of patients with mild-moderate COVID-19 due to the SARS-CoV-2 infection. “We are very pleased with the progress that has been made with our clinical strategy for Bucillamine in the potential treatment of COVID-19, specifically with our focus on a Phase 3 confirmatory study to be conducted in the U.S. and our expansion into Canada,” said Michael Frank, Revive’s Chief Executive Officer. The Company will have its Pre-CTA meeting with Health Canada this week.  A complete briefing package accompanied the meeting request to discuss Bucillamine’s Chemistry, Manufacturing and Controls, non-clinical and clinical safety information, clinical trial design, and Health Canada’s guidance regarding the possibility of including an additional exploratory arm in the proposed trial in a subset of patients from the pediatric population.  Results from the Pre-CTA meeting with Health Canada will be made available and the Company expects to initiate a clinical study as soon as possible following receipt of regulatory clearance from Health Canada. Additionally, Revive is finalizing its IND with the U.S. FDA for the proposed Phase 3 confirmatory clinical trial to evaluate Bucillamine in the treatment of patients with mild-moderate COVID-19 due to the SARS-CoV-2 infection.  The Company will file the IND later this month and expects final approval to proceed to the Phase 3 study shortly thereafter.

Numinus Wellness Inc. (TSXV:NUMI) announced the appointment of Dr. Devon Christie, MD CCFP RTC IFMCP, to the position of Medical Director at Numinus Wellness Inc. --another key step in the Company’s evolution as a leader in the advancement of psychedelic therapies, treatment and research. “We are embarking on an exciting journey at Numinus,” Dr. Wood says. “We are working with health authorities, regulators and Colleges to advance research and protocol development to explore the application of psychedelic assisted psychotherapies in safe, controlled therapeutic environments. Devon will play a key role in the Company in helping to design and implement our patient-focused model for when we are able to put these therapies in place.”

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with, is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of and The Yield Growth Corp., Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please click here for full disclaimer.

Contact Information:
[email protected]